Inhibikase Therapeutics Inc. Share

Inhibikase Therapeutics Inc. (IKT) is a biopharmaceutical company focused on developing therapeutics for Parkinson's disease and other related neurodegenerative disorders. The company's research and development efforts are centered around small molecule kinase inhibitors designed to target specific disease-causing pathways. Inhibikase aims to address unmet medical needs by creating novel treatments that can slow or halt the progression of these debilitating conditions. Their pipeline includes potential therapies for both the early and advanced stages of Parkinson's disease, as well as other neurodegenerative diseases with similar underlying mechanisms. By focusing on precision medicine and targeted therapies, Inhibikase seeks to improve the lives of patients affected by these challenging illnesses. The company is listed on the NASDAQ stock exchange.